Overcoming Treatment Challenges in Multiple Myeloma with Alternative Routes of Administration

Web Exclusives
Download Newsletter

Multiple myeloma (MM) is among the most challenging cancers to treat. Patients diagnosed with this disease are typically older, with a mean age of 62 years for men and 61 years for women.1 This older, often elderly population is prone to several factors that complicate treatment, including comorbid conditions, decreased physiologic reserve, cognitive and other psychosocial problems, and a greater risk for adverse drug reactions.2,3

Moreover, MM remains an incurable cancer, although the introduction of novel, molecularly targeted therapies over the past 2 decades has markedly prolonged survival.4 Improved outcomes, however, require the use of numerous, sequential therapies,1 to which patients and caregivers must commit significant time and expense.

Last modified: March 7, 2019
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology